JGC
KRYS icon

J. Goldman & Co’s Krystal Biotech KRYS Stock Holding History

J. Goldman & Co’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,600
Closed -$3.35M – 780
2025
Q4 		$3.35M Buy
+13,600
New +$2.86M 0.09% 251
2023
Q4 		– Sell
-27,000
Closed -$3.13M – 413
2023
Q3 		$3.13M Buy
+27,000
New +$3.29M 0.11% 165

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's KRYS Position: Q1 2026 in Review

J. Goldman & Co sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 1,535 shares — an estimated $378K sold.

J. Goldman & Co first reported a position in KRYS in Q2 2020 and held it in 16 quarters. The position peaked at $4.08M in Q3 2023. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • J. Goldman & Co reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 1,535 Krystal Biotech shares in Q1 2026, an estimated $378K.
  • J. Goldman & Co first reported a position in Krystal Biotech in Q2 2020 and held it in 16 quarters.
  • J. Goldman & Co's Krystal Biotech position peaked at $4.08M in Q3 2023.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.